RxDoctor Payments Data

Todd Gehr, MD

Nephrology · Richmond, VANPI 1487738233

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,350 of the $16,883 with a category attached, or 61.3%. Mallinckrodt Hospital Products Inc. accounts for 97.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $6,957 and has fallen 76.9% since, to $1,606 in 2025. Among nephrology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,883in general payments, 2019–2025

Across 21 payments — averaging $803.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$17K
  • Nxstage Medical, Inc.$220
  • Sanofi$91
  • Fresenius USA Marketing, Inc.$43
  • Calliditas Therapeutics US Inc.$14

What the payments were for

  • Consulting fees$4,69528%
  • Speaking & faculty fees$10,35061%
  • Travel & lodging$1,1077%
  • Food & beverage$7174%
  • Education$140%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,883 in reported general payments places this provider in the 90th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$108,564
Medicare patients
371
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide22$65,380
FarxigaDapagliflozin Propanediol42$30,950
Sevelamer Carbonate36$19,433
Midodrine Hcl46$4,556
Pyridostigmine Bromide35$3,321
Sodium Chloride0.9 % Sodium Chloride65$2,120
Potassium Citrate ErPotassium Citrate18$1,629
Fludrocortisone Acetate47$1,620
Clonidine13$1,171
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$968
Minoxidil17$966
Guanfacine Hcl11$886
Eplerenone13$711
Metoprolol Succinate62$625
Calcium Acetate15$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$43$65,38022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 298 nephrology providers in Virginia.

Other nephrology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →